Current standard values of health utility scores for evaluating costeffectiveness in liver disease:A meta-analysis  

作　　者：Tomohiro Ishinuki Shigenori Ota Kohei Harada Masaki Kawamoto Makoto Meguro Goro Kutomi Hiroomi Tatsumi Keisuke Harada Koji Miyanishi Toru Kato Toshio Ohyanagi Thomas T Hui Toru Mizuguchi 

机构地区：[1]Department of Nursing,Surgical Sciences,Sapporo Medical University,Sapporo 0608556,Japan [2]Departments of Surgery,Surgical Science and Oncology,Sapporo Medical University,Sapporo 0608543,Japan [3]Department of Radiology,Sapporo Medical University,Sapporo 0608543,Japan [4]Departments of Surgery,Nemuro City Hospital,Nemuro 0870008,Japan [5]Departments of Surgery,Sapporo Satozuka Hospital,Sapporo 0040811,Japan [6]Department of Intensive Care Medicine,Sapporo Medical University,Sapporo 0608543,Japan [7]Department of Emergency Medicine,Sapporo Medical University,Sapporo 0608543,Japan [8]Department of Medical Oncology,Sapporo Medical University,Sapporo 0608543,Japan [9]Department of Liberal Arts and Sciences,Center for Medical Education,Sapporo Medical University,Sapporo 0608556,Japan [10]Departments of Surgery,Stanford University School of Medicine,Stanford,94598,United States

出　　处：《World Journal of Gastroenterology》2022年第31期4442-4455,共14页世界胃肠病学杂志（英文版）

基　　金：Supported by Grants-in-Aid from JSPS KAKENHI,No.JP 20K10404(to Mizuguchi T)and No.JP 21K10715(to Ishinuki T);the Hokkaido Hepatitis B Litigation Orange Fund,No.2059198(to Mizuguchi T)and No.2136589(to Harada K);Terumo Life Science Foundation,No.2000666;Pfizer Health Research Foundation,No.2000777;the Viral Hepatitis Research Foundation of Japan,No.3039838;Project Mirai Cancer Research Grants,No.202110251;Takahashi Industrial and Economic Research Foundation,No.12-003-106;Daiichi Sankyo Company,No.2109540;Shionogi and Co.,No.2109493;MSD,No.2099412;Takeda Pharmaceutical Company,No.2000555;Sapporo Doto Hospital,No.2039118;Noguchi Hospital,No.2029083;Doki-kai Tomakomai Hospital,No.2059203;Tsuchida Hospital,No.2000092;Shinyu-kai Noguchi Hospital,No.2029083(to Mizuguchi T);the Yasuda Medical Foundation,No.28-1(to Ishinuki T).

摘　　要：BACKGROUND Health utility assessments have been developed for various conditions,including chronic liver disease.Health utility scores are required for socio-economic evaluations,which can aid the distribution of national budgets.However,the standard health utility assessment scores for specific health conditions are largely unknown.AIM To summarize the health utility scores,including the EuroQOL 5-dimensions 5-levels(EQ-5D-5L),EuroQol-visual analogue scale,short from-36(SF-36),RAND-36,and Health Utilities Index(HUI)-Mark2/Mark3 scores,for the normal population and chronic liver disease patients.METHODS A systematic literature search of PubMed and MEDLINE,including the Cochrane Library,was performed.Meta-analysis was performed using the RevMan software.Multiple means and standard deviations were combined using the StatsToDo online web program.RESULTS The EQ-5D-5L and SF-36 can be used for health utility evaluations during antiviral therapy for hepatitis C.HUI-Mark2/Mark3 indicated that the health utility scores of hepatitis B patients are roughly 30% better than those of hepatitis C patients.CONCLUSION The EQ-5D-5L is the most popular questionnaire for health utility assessments.Health assessments that allow free registration would be useful for evaluating health utility in patients with liver disease.

关 键 词：Quality of life EuroQOL 5-dimensions 5-levels Short from-36 RAND-36 Health Utilities Index-Mark 

分 类 号：R575[医药卫生—消化系统]